Front Matter....Pages i-ix
Front Matter....Pages 1-1
Historical Perspectives and Current Trends in Cancer Immunotherapy....Pages 3-15
T Cell and Antigen-Presenting Cell Subsets in the Tumor Microenvironment....Pages 17-44
Front Matter....Pages 45-45
Adoptive T Cell Transfer....Pages 47-70
Dendritic Cell-Based Cancer Immunotherapy: Achievements and Novel Concepts....Pages 71-108
Front Matter....Pages 109-109
Peptide and Protein-Based Cancer Vaccines....Pages 111-146
Antigen Targeting to Dendritic Cells for Cancer Immunotherapy....Pages 147-171
Cytokines in the Treatment of Cancer....Pages 173-210
Immune Co-signaling to Treat Cancer....Pages 211-280
Managing Regulatory T Cells to Improve Cancer Immunotherapy....Pages 281-314
Myeloid-Derived Suppressor Cells in Cancer: Mechanisms and Therapeutic Perspectives....Pages 315-333
Antibodies as Cancer Immunotherapy....Pages 335-376
Targeted Toxins in Cancer Immunotherapy....Pages 377-396
Front Matter....Pages 397-397
Miscellaneous Approaches and Considerations: TLR Agonists and Other Inflammatory Agents, Anti-Chemokine Agents, Infectious Agents, Tumor Stroma Targeting, Age and Sex Effects, and Miscellaneous Small Molecules....Pages 399-424
Monitoring Antigen-Specific Responses in Clinical Trials of Cancer Immunotherapy....Pages 425-453
Issues in Pre-clinical Models, Clinical Trial Design and Analytical Considerations in Developing and Evaluating Novel Cancer Immunotherapies....Pages 455-474
Back Matter....Pages 475-483